Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Dr. Clarke on Melanoma Biopsies

July 25th 2014

Loren Clarke, MD, vice president of Medical Affairs of Dermatology at Myriad Genetics, discusses melanoma biopsies.

Dabrafenib/Trametinib Extends OS Versus Vemurafenib in Phase III Melanoma Trial

July 18th 2014

A phase III study comparing trametinib (Mekinist) plus dabrafenib (Tafinlar) with single-agent vemurafenib (Zelboraf) has been stopped early following a positive interim analysis

Immunotherapy Branches Out

July 18th 2014

Immunotherapy agents are delivering impressive results in a broad range of tumor types, reinforcing the excitement in research and investment circles for anticancer strategies that actively harness the immune system

Vemurafenib/Cobimetinib Extends PFS in Phase III Melanoma Study

July 14th 2014

The combination of the BRAF inhibitor vemurafenib and the MEK inhibitor cobimetinib significantly improved PFS compared with vemurafenib alone for patients with untreated BRAFV600-mutated advanced melanoma.

Dr. Puzanov on T-VEC in Combination with Ipilimumab for Melanoma Treatment

July 9th 2014

Igor Puzanov, MD, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses the rationale behind a phase Ib study to evaluate the efficacy and safety of T-VEC and ipilimumab in previously untreated, unresected stage IIIB-IV melanoma.

Nivolumab, Alectinib Gain Approvals in Japan

July 7th 2014

The PD-1 inhibitor nivolumab and the second-generation ALK inhibitor alectinib have each gained their first approvals as treatments for patients in Japan.

Frontline Nivolumab Improves Survival in Phase III Melanoma Study

June 25th 2014

Frontline treatment with the anti-PD-1 agent nivolumab significantly extended overall survival when compared with dacarbazine for patients with metastatic or unresectable melanoma.

Conclusion: Improving Outcomes in Melanoma

June 17th 2014

Surgery Following Systemic Therapy in Melanoma

June 17th 2014

Nivolumab Plus Ipilimumab in Advanced Melanoma

June 17th 2014

Immunotherapy Combinations in Advanced Melanoma

June 17th 2014

Novel Therapies in Metastatic Melanoma

June 17th 2014

Strategies for the Detection of Recurrent Melanoma

June 17th 2014

Ipilimumab Side Effect Management in Melanoma

June 17th 2014

Adjuvant Treatment Selection in High-Risk Melanoma

June 17th 2014

Adjuvant Therapy for Stage III Melanoma

June 17th 2014

Role of Adjuvant Radiation Therapy in Melanoma

June 17th 2014

Molecular Testing in Resectable Melanoma

June 17th 2014

Lymph Node Management in Melanoma

June 17th 2014

Imaging and SLN Biopsy for Patients With Melanoma

June 17th 2014